Status:
COMPLETED
Prognostic Impact of Guideline-recommended Timing for Invasive Strategy in NSTEMI
Lead Sponsor:
University Hospital, Montpellier
Collaborating Sponsors:
University Hospital, Nīmes
Conditions:
NSTEMI
NSTE-ACS (NSTEMI and UA)
Eligibility:
All Genders
18+ years
Brief Summary
The objective of this multicentric observational study is to evaluate the prognostic influence of adherence or non-adherence to the recommended coronary angiography timeframe (within 24 hours) and the...
Detailed Description
Primary Objective: To describe the predictive values (sensitivity and specificity) of the timing of coronary angiography after the diagnosis of NSTEMI. Secondary Objective: To evaluate an optimal thr...
Eligibility Criteria
Inclusion
- Presence of chest pain with or without ECG changes
- Elevation of troponin level \> 90th percentile or a significant increase between two dosages
- Significant or non-significant coronary lesion confirming the diagnosis of coronary artery disease on coronary angiography (coronary angiography mandatory before inclusion to confirm NSTEMI)
Exclusion
- STEMI (ST-segment elevation myocardial infarction) or equivalent (defined as chest pain with ECG changes and troponin elevation \> 5 times the normal with an occluded artery (TIMI 0, 1, or 2) during initial coronary angiography)
- Very high-risk NSTEMI (hemodynamic instability, cardiogenic shock, recurrent/refractory chest pain despite optimal medical treatment, life-threatening arrhythmia, mechanical complication, heart failure clearly related to NSTEMI, ST depression \> 1mm/6 leads with ST elevation in aVR and/or V1) for which urgent coronary angiography is mandatory
- Unstable angina (acute coronary syndrome without troponin elevation)
- Troponin elevation without chest pain or symptoms suggestive of NSTEMI
- Recovered cardiac arrest
- Contraindication to coronary revascularization or coronary angiography
- Other diagnoses considered after coronary angiography (e.g., myocarditis, Takotsubo syndrome)
- Age \< 18 years
Key Trial Info
Start Date :
November 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 20 2025
Estimated Enrollment :
407 Patients enrolled
Trial Details
Trial ID
NCT07204847
Start Date
November 1 2023
End Date
June 20 2025
Last Update
October 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Montpellier
Montpellier, France, 34000